Damon Race: Pleased to Share GeneVentiv’s Scientific Debut at ASGCT 2026
Damon Race, President and CEO of GeneVentiv Therapeutics, Inc., shared on LinkedIn:
”We’re pleased to share GeneVentiv’s scientific debut at ASGCT 2026.
Our CSO, Paris Margaritis, DPhil, is presenting our work on a next-generation AAV8.FVa construct, advancing a differentiated approach to restoring thrombin generation in hemophilia A patients with or without inhibitors through native hepatic expression of a regulated coagulation cofactor.
The technology presented here forms part of GeneVentiv’s growing IP portfolio.
It’s exciting to reflect on this work as the foundation for our program, which has advanced to studies in hemophilia A canines.
We look forward to sharing additional data as development progresses.”
Stay updated with Hemostasis Today.
-
Nov 12, 2026, 16:35Mohamed Hesham Gamal: Intravenous Thrombolysis Shows Strong Safety Profile in Stroke Mimics
-
Nov 12, 2026, 14:35Mokhtar Tazik: Connecting Clinical Demand with Plasma Collection and Fractionation Capacity
-
Nov 12, 2026, 14:25Kim Phelan: Celebrating Dr. Marilyn Manco-Johnson as a Recipient of the 2026 Eternal Spirit Award
-
Nov 12, 2026, 14:20Shailesh Kucha: Ensuring Transfusion Safety Through Biochemical Assessment of Stored Red Cells
-
Nov 12, 2026, 14:20Akshat Jain: Wonderful Time Presenting at the ATHN 2026
-
Nov 12, 2026, 14:08Elisa Gabinaud: The Evolving Science of Megakaryocyte Development
-
Nov 12, 2026, 13:57Seyed Mohammad Sadegh Pezeshki: When Microcytosis Reveals a Complex Hemoglobinopathy
-
Nov 12, 2026, 13:45Danny Hsu: THANZ Highlights Antiphospholipid Syndrome in Upcoming Educational Webinar
-
Nov 12, 2026, 13:04Wuhan Thrombosis Congress 2026 – Bringing Global Experts Together – ISTH